Biohaven Pharmaceutical Holding Return on Tangible Equity 2016-2022 | BHVN

Current and historical return on tangible equity values for Biohaven Pharmaceutical Holding (BHVN) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
Biohaven Pharmaceutical Holding Return On Tangible Equity Historical Data
Date TTM Net Income Tangible Equity Return on Tangible Equity
2022-03-31 $-0.79B $-0.52B 127.43%
2021-12-31 $-0.85B $-0.80B 147.50%
2021-09-30 $-0.87B $-0.65B 179.57%
2021-06-30 $-0.89B $-0.51B 231.66%
2021-03-31 $-0.86B $-0.34B 313.22%
2020-12-31 $-0.77B $-0.43B 451.18%
2020-09-30 $-0.70B $-0.25B 464.56%
2020-06-30 $-0.61B $-0.08B 1068.42%
2020-03-31 $-0.64B $0.08B -7302.86%
2019-12-31 $-0.53B $-0.35B -4141.18%
2019-09-30 $-0.43B $0.12B -313.36%
2019-06-30 $-0.39B $0.19B -310.58%
2019-03-31 $-0.22B $0.10B -200.46%
2018-12-31 $-0.24B $0.15B -216.22%
2018-09-30 $-0.21B $0.07B -199.53%
2018-06-30 $-0.19B $0.12B -150.68%
2018-03-31 $-0.20B $0.11B -136.50%
2017-12-31 $-0.14B $0.13B -110.98%
2017-09-30 $-0.14B $0.16B -150.41%
2017-06-30 $-0.12B $0.19B -233.18%
2017-03-31 $-0.08B $0.02B -1866.67%
2016-12-31 $-0.06B $-0.00B 12800.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $10.248B $0.463B
Biohaven Pharmaceutical is a commercial-stage biotechnology company focused on developing, and commercializing products, primarily in the fields of central nervous system diseases, including neurological and rare disorders.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00